National Vision Holdings Inc header image

National Vision Holdings Inc

EYE

Equity

ISIN null / Valor 38523646

NASDAQ (2026-05-05)
USD 22.44+2.42%

National Vision Holdings Inc
UMushroom community rating:

star star star star star
0.00 0 votes No rating yet
NegativeNeutralPositive

About company

National Vision Holdings Inc is a prominent optical retail company in North America, operating well-known brands such as America's Best Contacts & Eyeglasses and Eyemart Express. The company provides a range of eye care services, including comprehensive eye examinations, prescription eyewear, and contact lenses. Beyond its commercial activities, National Vision is committed to expanding access to eye care in underserved communities through philanthropic efforts. In 2024, in collaboration with organizations like VOSH/International and SVOSH, the company facilitated over 67,000 free vision screenings and distributed thousands of eyeglasses worldwide, significantly improving vision health and accessibility for numerous individuals.

Summarized from source with an LLMView SourceSector: Healthcare

Latest Results (15.04.2026):

National Vision Holdings, Inc. — fourth quarter of fiscal 2025: The company reported continued top-line growth and improving profitability in Q4 fiscal 2025, with net revenue of $503.4 million (up 15.1% year‑over‑year) and net income from continuing operations of $3.3 million (diluted EPS $0.04) versus a loss in the year‑ago quarter. Adjusted measures showed larger improvement (Adjusted Operating Income of $17.6 million and Adjusted Diluted EPS of $0.15). For full fiscal 2025, net revenue was $1,987.5 million (up 9.0%), Adjusted Operating Income was $102.5 million and Adjusted Diluted EPS was $0.80. The results reflect store growth, pricing/product‑mix actions, operating leverage and certain timing items (53rd week and unearned revenue timing).

Revenue

Q4 net revenue: $503.4M, +15.1% YoY (benefiting from the 53rd week, new store sales and Adjusted Comparable Store Sales). Fiscal 2025 net revenue: $1,987.5M, +9.0% YoY.

Comparable Store Sales

Q4 comparable store sales growth was 6.6% and Adjusted Comparable Store Sales Growth was 4.8% (driven by higher average ticket and strength in the managed care cohort). Fiscal 2025 comparable store sales growth was 5.9% and adjusted 6.0%.

Profitability & EPS

Q4 net income from continuing operations: $3.3M (diluted EPS $0.04) versus a $(0.37) loss per share in Q4 2024. Q4 Adjusted Diluted EPS from continuing operations: $0.15 (vs. $(0.04) prior year). Fiscal 2025 diluted EPS from continuing operations: $0.37; Adjusted Diluted EPS: $0.80 (up from $0.52).

Adjusted Operating Income & Margins

Q4 Adjusted Operating Income from continuing operations: $17.6M with Adjusted Operating Margin of 3.5% (vs. $3.2M and 0.7% prior year). Fiscal 2025 Adjusted Operating Income: $102.5M and Adjusted Operating Margin 5.2% (vs. $65.5M and 3.6% in FY2024).

Costs, SG&A and Operating Leverage

Costs applicable to revenue rose in absolute terms but declined as a percentage of net revenue (Q4: 41.9%, down 40 bps) driven by pricing and product‑mix. SG&A increased in dollars but fell to 51.9% of net revenue in Q4 (Adjusted SG&A 50.0% of net revenue), reflecting operating leverage even as variable incentive and health care costs rose.

Store Count & Network Changes

Ended Q4 with 1,250 stores (opened 12 stores and closed 4 America’s Best stores during the quarter). For fiscal 2025 the company opened 33 new stores and closed 23 (12 America’s Best and 11 Fred Meyer), with overall store count growth of ~0.8% year over year.

Balance Sheet & Cash

Cash balance was $38.7M as of January 3, 2026; total debt was $245.9M. The company had no borrowings under its $300M revolver (letters of credit ~$6.7M outstanding) and entered a $100M notional interest‑rate swap in Q4 to reduce interest cash‑flow variability.

Timing and One‑time Items

The 53rd week contributed to revenue growth; conversely the timing of unearned/deferred revenue negatively affected reported revenue and margins (Q4 timing reduced revenue by ~0.8% and negatively impacted Diluted EPS/Adjusted Diluted EPS by $0.02; fiscal 2025 impact on EPS was ~$0.08). The company also recorded some non‑cash asset impairment items in prior periods and other adjustments included in its non‑GAAP reconciliations.

Fiscal 2026 Outlook (highlights)

Guidance items provided: projected new stores ~30–35 (primarily America’s Best), Adjusted Comparable Store Sales Growth 3.0%–6.0%, assumed tax rate ~28%, and the company assumes ~82 million shares for Adjusted Diluted EPS calculations. The release notes forward‑looking non‑GAAP measures are not reconciled to GAAP.

Summarized from source with an LLMView Source

Key figures

69.4%1Y
0.18%3Y
-55.7%5Y

Performance

47.0%1Y
50.4%3Y
53.8%5Y

Volatility

Market cap

1783 M

Market cap (USD)

Daily traded volume (Shares)

1,412,488

Daily traded volume (Shares)

1 day high/low

10.51 / 9.93

1 day high/low (USD)

52 weeks high/low

0.00 / 0.00

52 weeks high/low (USD)

Dividend ex-date

01 January, 2022

Dividend ex-date

Dividend

0.00

Dividend (USD)

Dividend yield (p.a.)

0.00%

Dividend yield (p.a.)

0.002022
0.002023
0.002024

Est dividend (USD)

0.00%2022
0.00%2023
0.00%2024

Est dividend yield

P/E ratio

10.00

P/E ratio

00.002022
00.002023
00.002024

Est P/E ratio

EPS

0.00

EPS (USD)

0.002022
0.002023
0.002024

Est EPS (USD)

Ratings & reviews

star star star star star

0.00

0 votes
Performance:
starstarstarstarstar
0.00
Innovation:
starstarstarstarstar
0.00
Society:
starstarstarstarstar
0.00
Nature:
starstarstarstarstar
0.00

EQUITIES OF THE SAME SECTOR

Alnylam Pharmaceuticals Inc
Alnylam Pharmaceuticals Inc Alnylam Pharmaceuticals Inc Valor: 1806798
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.07%USD 301.11
BeiGene Ltd
BeiGene Ltd BeiGene Ltd Valor: 30165310
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.12%USD 297.49
Align Technology Inc
Align Technology Inc Align Technology Inc Valor: 1159441
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-1.84%USD 168.71
Icon PLC
Icon PLC Icon PLC Valor: 1017575
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
8.35%USD 121.32
Royalty Pharma PLC
Royalty Pharma PLC Royalty Pharma PLC Valor: 55041695
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.48%USD 50.44
Viatris Inc
Viatris Inc Viatris Inc Valor: 58198423
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
2.11%USD 15.52
Sareum Holdings PLC
Sareum Holdings PLC Sareum Holdings PLC Valor: 116566624
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.00%GBP 0.20
Venture Life Group PLC
Venture Life Group PLC Venture Life Group PLC Valor: 23084203
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.00%GBP 0.56
Alignment Healthcare Inc
Alignment Healthcare Inc Alignment Healthcare Inc Valor: 110387702
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-4.98%USD 18.30
Bruker Corp
Bruker Corp Bruker Corp Valor: 1635622
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
4.45%USD 38.01